0000000000559938

AUTHOR

Vincenzo Isola

showing 3 related works from this author

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR D…

2007

Abstract PURPOSE: To assess the effectiveness of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV) associated with retinal pigment epithelium detachment (PED) in age-related macular degeneration. METHODS: Thirty eyes of 26 patients with CNV and PED were treated with PDT. The eyes were divided in two groups based on CNV location in relation to PED; group 1 included 13 eyes with CNV within PED, and group 2 included 17 eyes with CNV at the edge of PED. The median follow-up was 16 months. RESULTS: Patients received a mean +/- SD of 2.83 +/- 1.26 treatments (range, 1-6 treatments). In the whole cohort, the mean preoperative visual acuity changed from 20/144 (0.86…

Malemedicine.medical_specialtyPorphyrinsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyMacular DegenerationAge relatedOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyPigment Epithelium of EyeAgedAged 80 and overPhotosensitizing AgentsRetinal pigment epitheliumSettore MED/30 - Malattie Apparato Visivobusiness.industryRetinal DetachmentVerteporfinGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyFemaleRetinal pigment epithelial detachmentsense organsPhotodynamic therapy choroidal neovascularization age-related macular degenerationmedicine.symptombusinessFollow-Up Studiesmedicine.drugRetina
researchProduct

Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.

2007

Purpose To assess the effect of verteporfin photodynamic therapy (PDT) in juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Design Prospective, open-label, consecutive, interventional case series. Methods We prospectively followed a series of 48 consecutive patients (49 eyes) with pathologic myopia (≥ 6 diopters) who received verteporfin PDT for juxtafoveal CNV. This population was divided into two groups based on age (group A ≤ 55 years old, group B >55 years old), in three subgroups based on CNV lesion size, and in three categories based on refractive error at baseline. Results The median follow-up was 32 months (range, 12 to 56 months). Visual acuity (VA…

AdultMalemedicine.medical_specialtyRefractive errorFovea CentralisVisual acuityPorphyrinsgenetic structuresEye diseasePopulationVisual AcuityVision disorderlavoro clinico con dati originaliOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyeducationDioptreAgedAged 80 and overeducation.field_of_studyPhotosensitizing Agentsbusiness.industryVerteporfinMiddle Agedmedicine.diseasePrognosisVerteporfineye diseasesChoroidal NeovascularizationOphthalmologyChoroidal neovascularizationPhotochemotherapyMyopia DegenerativeFemalesense organsmedicine.symptombusinessmedicine.drugFollow-Up StudiesAmerican journal of ophthalmology
researchProduct

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.

2006

Purpose: To assess the safety and effectiveness of photodynamic therapy (PDT) with verteporfin for subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Methods: Sixty-two patients (62 eyes) with PM underwent PDT according to the guidelines of the Verteporfin in Photodynamic Therapy Study. Clinical evaluations performed at all study visits included measurement of best-corrected Snellen visual acuity, slit-lamp biomicroscopy, and fundus fluorescein angiography. Patients were followed up at 1 month and 3 months after treatment and thereafter at 3-month intervals. Results: The final visual acuity of the study patients, after a median follow-up of 31 months, improved…

AdultMaleRefractive errormedicine.medical_specialtyFovea CentralisVisual acuityPorphyrinsgenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyOphthalmologyPathologic myopiamedicineHumansProspective StudiesFluorescein AngiographyDioptreAgedAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMiddle Agedmedicine.diseaseVerteporfineye diseasesChoroidal NeovascularizationOphthalmologyLong term learningChoroidal neovascularizationPhotochemotherapyMyopia DegenerativeFemalesense organsmedicine.symptombusinessmyopia subfoveal choroidal neovascularization photodynamic therapy verteporfin.medicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct